Predicting fatal drug poisoning among people living with HIV-HCV co-infection

被引:0
|
作者
Bedard, Melanie [1 ,2 ]
Moodie, Erica E. M. [1 ]
Cox, Joseph [1 ,2 ]
Gill, John [3 ]
Walmsley, Sharon [4 ,5 ]
Martel-Laferriere, Valerie [6 ]
Cooper, Curtis [7 ,8 ]
Klein, Marina B. [1 ,2 ,9 ]
机构
[1] McGill Univ, Dept Epidemiol Biostat & Occupat Hlth, Montreal, PQ, Canada
[2] McGill Univ, Res Inst, Ctr Outcomes Res & Evaluat, Hlth Ctr, Montreal, PQ, Canada
[3] Univ Calgary, Dept Med, Calgary, AB, Canada
[4] Univ Toronto, Dept Med, Div Infect Dis, Toronto, ON, Canada
[5] Toronto Gen Hosp Res Inst, Univ Hlth Network, Toronto, ON, Canada
[6] Ctr Hosp Univ Montreal, Ctr Rech, Montreal, PQ, Canada
[7] Univ Ottawa, Dept Med, Ottawa, ON, Canada
[8] Ottawa Hosp Res Inst, Ottawa, ON, Canada
[9] Canadian Inst Hlth Res, Canadian HIV AIDS & STBBI Clin Trials Network, Montreal, PQ, Canada
来源
CANADIAN LIVER JOURNAL | 2025年 / 0卷 / AOP期
基金
加拿大健康研究院;
关键词
HIV-HCV co-infection; drug poisoning; overdose; random forest; machine learning; OPIOID OVERDOSE; MONITORING PROGRAM; NONFATAL OVERDOSE; RISK; PRESCRIPTION; MORTALITY; SMOKING; DEATHS; MODELS; ROUTES;
D O I
10.3138/canlivj-2024-0060
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Drug poisoning (overdose) is a public health crisis, particularly among people living with HIV and hepatitis C (HCV) co-infection. Identifying potential predictors of drug poisoning could help decrease drug-related deaths.Methods: Data from the Canadian Co-infection Cohort were used to predict death due to drug poisoning within 6 months of a cohort visit. Participants were eligible for analysis if they ever reported drug use. Supervised machine learning (stratified random forest with undersampling to account for imbalanced data) was used to develop a classification algorithm using 40 sociodemographic, behavioural, and clinical variables. Predictors were ranked in order of importance, and odds ratios and 95% confidence intervals (CIs) were generated using a generalized estimating equation regression.Results: Of 2,175 study participants, 1,998 met the eligibility criteria. There were 94 drug poisoning deaths, 53 within 6 months of a last visit. When applied to the entire sample, the model had an area under the curve (AUC) of 0.9965 (95% CI, 0.9941-0.9988). However, the false-positive rate was high, resulting in a poor positive predictive value (1.5%). Our model did not generalize well out of sample (AUC 0.6, 95% CI 0.54-0.68). The top important variables were addiction therapy (6 months), history of sexually transmitted infection, smoking (6 months), ever being on prescription opioids, and non-injection opioid use (6 months). However, no predictor was strong.Conclusions: Despite rich data, our model was not able to accurately predict drug poisoning deaths. Larger datasets and information about changing drug markets could help improve future prediction efforts.
引用
收藏
页数:14
相关论文
共 50 条
  • [11] Injection drug use, food insecurity, and HIV-HCV co-infection: a longitudinal cohort analysis
    McLinden, Taylor
    Moodie, Erica E. M.
    Harper, Sam
    Hamelin, Anne-Marie
    Anema, Aranka
    Aibibula, Wusiman
    Klein, Marina B.
    Cox, Joseph
    AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV, 2018, 30 (10): : 1322 - 1328
  • [12] Liver enzymes elevation after HAART in HIV-HCV co-infection
    Servin-Abad, L
    Molina, E
    Baracco, G
    Arosemena, L
    Regev, A
    Jeffers, L
    Schiff, E
    JOURNAL OF VIRAL HEPATITIS, 2005, 12 (04) : 429 - 434
  • [13] Decreased miR-122 Levels With HCV Clearance in HIV-HCV Co-Infection
    Dubin, Perry H.
    Yuan, Hejun
    Devine, R. Kenton
    Jain, Mamta K.
    Hynan, Linda S.
    Lee, William M.
    GASTROENTEROLOGY, 2013, 144 (05) : S976 - S976
  • [14] HIV-HCV co-infection facing HCV protease inhibitor licensing: implications for clinicians
    Ingiliz, Patrick
    Rockstroh, Juergen K.
    LIVER INTERNATIONAL, 2012, 32 (08) : 1194 - 1199
  • [15] Stable recovery from HCV in HIV-HCV co-infection under antiretroviral therapy
    Zeitoun, Jean-David
    Mallet, Vincent
    Chaix, Marie-Laure
    Viard, Jean-Paul
    Blanche, Stephane
    Pol, Stanislas
    JOURNAL OF CLINICAL VIROLOGY, 2007, 40 (01) : 71 - 73
  • [16] Mitochondrial Abnormalities in Patients with HIV-HCV Co-infection as Compared to Patients with HCV Mono-infection
    Chapplain, Jean-Marc
    Tattevin, Pierre
    Guyader, Dominique
    Begue, Jean-Marc
    Beillot, Jocelyne
    Turlin, Bruno
    Souala, Faouzi
    Arvieux, Cedric
    Rochcongar, Pierre
    Michelet, Christian
    HIV CLINICAL TRIALS, 2011, 12 (01): : 54 - 60
  • [17] Prevalence of HBV/HCV Co-Infection and Associated Risk Factors in People Living with HIV
    Senoglu, Sevtap
    Yesilbag, Zuhal
    Karaosmanoglu, Hayat Kumbasar
    Aydin, Ozlem Altuntas
    HEPATITIS MONTHLY, 2020, 20 (04)
  • [18] ANRS HC 02 RIBAVIC: Impact of steatosis in HIV-HCV co-infection
    Pol, S.
    GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE, 2009, 33 : S110 - S112
  • [19] Efficacy and Tolerability of Daclatasvir/Sofosbuvir (Datex) in Patients with HIV-HCV Co-infection
    Shokatpour, Narjes
    Sali, Shahnaz
    Daneshpazhouh, Batool
    Mardani, Masoud
    ARCHIVES OF CLINICAL INFECTIOUS DISEASES, 2020, 15 (03): : 1 - 7
  • [20] HIV-HCV Co-infection Therapeutic Outcomes Have Not Improved Over Time
    Cooper, Curtis
    Costiniuk, Cecilia
    Giguere, Pierre
    HIV CLINICAL TRIALS, 2009, 10 (03): : 203 - 206